Pharma Two B Announces Positive Results in Phase IIb Clinical Study of P2B001 for Early Stage Parkinson’s
Rehovot, Israel based Pharma Two B Ltd. is reportedly mulling issuance of an IPO after announcing successful results in the company’s Phase IIb pivotal study of P2B001 for treatment of early stage Parkinson’s Disease (PD) which is boosting the company’s confidence in taking its quest for financing to…